IP Library Granted Patent US 10,329,623
Granted Patent B2
US 10,329,623 · App. 14/880,450 · Granted Jun 25, 2019

Synthetic tissue controls and synthetic tissue microarray controls

Inventors: Syed Ashraf Imam (North Hollywood, CA); Mark Lee Rees (Huntington, NY)
Assignee: SLMP, LLC
C12Q1/6886G01N33/52G01N33/57492C12Q2600/158G01N33/4833
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,329,623
App. No.
14/880,450
Granted
Jun 25, 2019
Kind
B2
Abstract

The disclosed embodiments include methods to form STC and STMC for use in determining presence of cancer, and methods to detect presence of cancer. In one embodiment, A portion of a STC is stained. The STC includes normal cells and cancer cells of a type of cancer co-cultured based on at least one cell culturing factors. The at least one co-culture factors includes a type of the cancer cells being cultured, a ratio of the cancer cells to the normal cells being co-cultured, seeding density of the normal cells and the cancer cells being co-cultured, a type of cell growth supplement used to facilitate culturing the cells, and a concentration of the cell growth supplement used to facilitate co-culturing the cells. The stained portion is observed to determine presence of one or more biomarker types that indicate presence of cancer.

Claims (19)

1. A method to form a synthetic tissue control for use in determining presence of cancer, the method comprising:

preparing an approximately zero gravity environment for cell culture;

culturing cells comprising normal cells and cancer cells of a type of cancer in the approximately zero gravity environment and based on seeding density of the normal cells and the cancer cells being cultured; and

adding approximately 5 micrograms of DNase per milliliter of cell culture medium to facilitate un-clumping of the normal cells and the cancer cells during co-culturing of the cells.

2. The method of claim 1 , wherein culturing the cells comprises co-culturing the normal cells and the cancer cells in a cell culture chamber configured to maintain a concentration of CO 2 and temperature inside the cell culture chamber.

3. The method of claim 2 , wherein culturing the cells further comprises maintaining the cell culture chamber in a motorized rotating device operable to:

hold the synthetic tissue control; and

spin the cell culture chamber at a predetermined speed during co-culturing of the cells.

4. The method of claim 3 , further comprising:

forming a homogenous core with un-clumped normal cells; and

invading the homogenous core with un-clumped cells of the cancer cells.

5. The method of claim 1 , further comprising adding Fibronectin to improve contact between the normal cells and the cancer cells.

6. The method of claim 1 , wherein culturing the cells comprises culturing the cells in the approximately zero gravity environment for a period of 8-12 days.

7. The method of claim 1 , wherein culturing cells comprising normal cells and cancer cells comprises culturing normal cells and breast cancer cells.

8. The method of claim 7 , wherein a ratio of the breast cancer cells to the normal cells is approximately 1:99.8.

9. The method of claim 7 , wherein the breast cancer cells are MCF.7 cancer cells.

10. The method of claim 9 , wherein the seeding density of MCF.7 cancer cells is approximately 18,750 per milliliter.

11. The method of claim 1 , wherein the seeding density of the normal cells is approximately 187,876 per milliliter.

12. The method of claim 1 , further comprising staining the synthetic tissue control with a stain to observe one or more expressions of specific markers of the cancer cells.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Dec 31, 2020
From: GOLUB CAPITAL LLC, AS ADMINISTRATIVE AGENT
To: SLMP, LLC
Reel/Frame 054787/0616 →
SECURITY INTEREST Recorded Dec 31, 2020
From: SLMP, LLC
To: GOLUB CAPITAL LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 054787/0435 →
RELEASE OF SECURITY INTEREST Recorded May 31, 2017
From: FREEPORT FINANCIAL PARTNERS, LLC
To: SLMP, LLC
Reel/Frame 042549/0978 →
SECURITY INTEREST Recorded May 31, 2017
From: SLMP, LLC
To: GOLUB CAPITAL LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 042538/0372 →
SECURITY INTEREST Recorded Sep 13, 2016
From: SLMP, LLC
To: FREEPORT FINANCIAL PARTNERS, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 039720/0064 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE NAME PREVIOUSLY RECORDED AT REEL: 036979 FRAME: 0983. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT . Recorded Jul 26, 2016
From: IMAM, SYED ASHRAF, PHD; REES, MARK LEE, PHD
To: SLMP, LLC
Reel/Frame 039480/0181 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2015
From: IMAM, PHD., SYED ASHRAF; REES, PHD, MARK LEE
To: STATLAB MEDICAL PRODUCTS, LLC
Reel/Frame 036979/0983 →
Continuity (2)
Provisional Application 62211530 · Aug 28, 2015
Related Publication 20170059456A1 · Mar 2, 2017